CD274 and neoplasm: A KEYNOTE 158 trial revealed a response rate of 15% and promising OS rates (median, 9.4 months for the entire study population and 11.0 months for the PD-L1-positive population) in patients with advanced cervical cancer and PD-L1 positivity of tumor tissue.